Pemafibrate Protects against Fatty Acid-Induced Nephropathy by Maintaining Renal Fatty Acid Metabolism
出版年份 2021 全文链接
标题
Pemafibrate Protects against Fatty Acid-Induced Nephropathy by Maintaining Renal Fatty Acid Metabolism
作者
关键词
-
出版物
Metabolites
Volume 11, Issue 6, Pages 372
出版商
MDPI AG
发表日期
2021-06-10
DOI
10.3390/metabo11060372
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment
- (2019) Koutaro Yokote et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination
- (2019) Yamashita et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Molecular association model of PPARα and its new specific and efficient ligand, pemafibrate: Structural basis for SPPARMα
- (2018) Yuta Yamamoto et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial
- (2018) Shun Ishibashi et al. Journal of Clinical Lipidology
- Renoprotective effect of a novel selective PPARα modulator K-877 in db/db mice: A role of diacylglycerol-protein kinase C-NAD(P)H oxidase pathway
- (2017) Toshinobu Maki et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial
- (2016) Shun Ishibashi et al. ATHEROSCLEROSIS
- Peroxisome proliferator-activated receptor -dependent renoprotection of murine kidney by irbesartan
- (2016) M. Harada et al. CLINICAL SCIENCE
- Transcriptome Analysis of K-877 (a Novel Selective PPARα Modulator (SPPARMα))-Regulated Genes in Primary Human Hepatocytes and the Mouse Liver
- (2015) Sana Raza-Iqbal et al. Journal of Atherosclerosis and Thrombosis
- KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient
- (2014) Christoph Wanner et al. KIDNEY INTERNATIONAL
- Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development
- (2014) Hyun Mi Kang et al. NATURE MEDICINE
- New Fibrate Use and Acute Renal Outcomes in Elderly Adults
- (2013) Ying Y. Zhao ANNALS OF INTERNAL MEDICINE
- Effects of Fibrates in Kidney Disease
- (2012) Min Jun et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- PPARα Activation Protects against Anti-Thy1 Nephritis by Suppressing Glomerular NF-κB Signaling
- (2012) Koji Hashimoto et al. PPAR Research
- Fenofibrate, a PPARα agonist, has renoprotective effects in mice by enhancing renal lipolysis
- (2011) Yuki Tanaka et al. KIDNEY INTERNATIONAL
- Pretreatment by low-dose fibrates protects against acute free fatty acid-induced renal tubule toxicity by counteracting PPARα deterioration
- (2011) Kyoko Takahashi et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study
- (2010) T. M. E. Davis et al. DIABETOLOGIA
- Transgenic expression of proximal tubule peroxisome proliferator–activated receptor-α in mice confers protection during acute kidney injury
- (2009) Shenyang Li et al. KIDNEY INTERNATIONAL
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now